Cumberland Pharmaceuticals (CPIX)
(Delayed Data from NSDQ)
$1.31 USD
+0.03 (2.34%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.35 +0.04 (3.05%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.31 USD
+0.03 (2.34%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.35 +0.04 (3.05%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Cumberland Pharmaceuticals (CPIX) Reports Break-Even Earnings for Q2
by Zacks Equity Research
Cumberland (CPIX) delivered earnings and revenue surprises of 100.00% and 5.66%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cumberland Pharmaceuticals (CPIX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics
4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness
by Kinjel Shah
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in the second quarter of 2021. However, with demand trends expected to improve, XNCR, ORGO, CPIX, and ACER may prove to be good additions to one's portfolio.
United Therapeutics (UTHR) Tyvaso DPI Gets FDA's Priority Tag
by Zacks Equity Research
United Therapeutics' (UTHR) Tyvaso DPI is a drug device combination therapy, comprising the dry powder formulation of Tyvaso and a small, portable, dry powder inhaler.
Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor
by Zacks Equity Research
Omeros (OMER) announces initial results from a phase I study of OMS906.
Is Cumberland (CPIX) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Cumberland (CPIX) could produce exceptional returns because of its solid growth attributes.
Cumberland Pharmaceuticals (CPIX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Cumberland (CPIX) delivered earnings and revenue surprises of 200.00% and 4.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Cumberland Pharmaceuticals (CPIX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cumberland (CPIX) delivered earnings and revenue surprises of 128.57% and 7.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cumberland Pharmaceuticals (CPIX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cumberland Pharmaceuticals (CPIX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cumberland (CPIX) delivered earnings and revenue surprises of 166.67% and 3.54%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Cumberland (CPIX) Rating Upgrade to Buy
by Zacks Equity Research
Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cumberland Pharmaceuticals (CPIX) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Cumberland (CPIX) delivered earnings and revenue surprises of -50.00% and -11.93%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: NeoPhotonics, eXp World, Cumberland and Medifast
by Zacks Equity Research
Zacks.com featured highlights include: NeoPhotonics, eXp World, Cumberland and Medifast
4 Top-Ranked Liquid Stocks to Bet on for Alluring Returns
by Zacks Equity Research
Here are four top-ranked liquid gems that investors can add to portfolio for remarkable returns.
Analysts Estimate Cumberland Pharmaceuticals (CPIX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: MagnaChip Semiconductor, PJT Partners, eXp World and Cumberland Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights include: MagnaChip Semiconductor, PJT Partners, eXp World and Cumberland Pharmaceuticals
4 Top-Ranked Liquid Bets to Build a Successful Portfolio
by Zacks Equity Research
Here are four excellent liquid stocks that can contribute to making an outstanding portfolio for yield-seeking investors.
Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Ampio (AMPE) Looks Good: Stock Adds 5.2% in Session
by Zacks Equity Research
Ampio (AMPE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day
by Zacks Equity Research
LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day
3 Drugmakers Still Worth Betting on Amid Coronavirus Woes
by Indrajit Bandyopadhyay
Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.
Translate Bio (TBIO) Surges: Stock Moves 5.5% Higher
by Zacks Equity Research
Translate Bio (TBIO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Cumberland Pharmaceuticals (CPIX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cumberland (CPIX) delivered earnings and revenue surprises of 800.00% and 20.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cumberland Pharmaceuticals (CPIX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.